Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000598622 | SCV000709855 | pathogenic | not provided | 2024-09-26 | criteria provided, single submitter | clinical testing | Published functional studies demonstrate a damaging effect as c.373delT is shown to be biologically inactive (PMID: 8636437); Frameshift variant predicted to result in abnormal protein length as the last 14 amino acids are replaced with 9 different amino acids; This variant is associated with the following publications: (PMID: 8636437, 22606512, 27362444, 31166470, 31703413, 31980526, 31384098, 15297803, 31589614, 36001021, 34780050) |
Fulgent Genetics, |
RCV000503516 | SCV002782397 | pathogenic | Isolated thyroid-stimulating hormone deficiency | 2024-05-08 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000598622 | SCV003302470 | pathogenic | not provided | 2024-03-16 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Cys125Valfs*10) in the TSHB gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 14 amino acid(s) of the TSHB protein. This variant is present in population databases (rs755485552, gnomAD 0.03%). This premature translational stop signal has been observed in individuals with clinical features of congenital hypothyroidism (PMID: 8636437, 15297803, 22606512, 27362444, 31166470). It has also been observed to segregate with disease in related individuals. This variant is also known as C105V or 313delT. ClinVar contains an entry for this variant (Variation ID: 437070). Algorithms developed to predict the effect of variants on protein structure and function are not available or were not evaluated for this variant. Experimental studies have shown that this premature translational stop signal affects TSHB function (PMID: 8636437). For these reasons, this variant has been classified as Pathogenic. |
Greenwood Genetic Center Diagnostic Laboratories, |
RCV000503516 | SCV003799170 | pathogenic | Isolated thyroid-stimulating hormone deficiency | 2022-11-15 | criteria provided, single submitter | clinical testing | PS3, PM3_Strong |
Revvity Omics, |
RCV000503516 | SCV003823735 | pathogenic | Isolated thyroid-stimulating hormone deficiency | 2022-11-15 | criteria provided, single submitter | clinical testing | |
OMIM | RCV000503516 | SCV000033770 | pathogenic | Isolated thyroid-stimulating hormone deficiency | 2002-10-01 | no assertion criteria provided | literature only | |
Genetic Services Laboratory, |
RCV002463363 | SCV002064500 | pathogenic | Pituitary hypothyroidism | 2021-12-28 | no assertion criteria provided | clinical testing | DNA sequence analysis of the TSHB gene demonstrated a single base pair deletion in exon 3, c.373del. This pathogenic sequence change results in an amino acid frameshift and creates a premature stop codon 10 amino acids downstream of the change, p.Cys125Valfs*10. This pathogenic sequence change is predicted to result in an abnormal transcript, which may be degraded, or may lead to the production of a truncated TSHB protein with potentially abnormal function. This sequence change has been described in the gnomAD database with a frequency of o.031% in the non-Finnish European subpopulation (dbSNP rs755485552). This pathogenic sequence change has previously been described in the homozygous and compound heterozygous state in multiple individuals with TSHB-related hypothyroidism (PMID: 31166470, 22606512, 31703413, 15297803, 27362444). |